Combining epigenetic therapies with immunotherapies likely to improve cancer patient outcomes

Recent data suggest that epigenetic therapies are likely to provide additional clinical benefit to cancer patients when rationally combined with immunotherapeutic drugs, according to a review published in Clinical Cancer Research, a journal of the American Association for Cancer Research. —> Read More